ANI Pharmaceuticals (NASDAQ:ANIP) SVP Thomas Andrew Rowland Sells 459 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Thomas Andrew Rowland sold 459 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $79.21, for a total transaction of $36,357.39. Following the completion of the transaction, the senior vice president directly owned 38,271 shares of the company’s stock, valued at approximately $3,031,445.91. The trade was a 1.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Thomas Andrew Rowland also recently made the following trade(s):

• On Wednesday, March 11th, Thomas Andrew Rowland sold 4,772 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $74.91, for a total transaction of $357,470.52.

ANI Pharmaceuticals Trading Up 1.7%

Shares of ANIP stock traded up $1.38 during trading hours on Wednesday, hitting $80.88. 308,836 shares of the company’s stock traded hands, compared to its average volume of 412,504. The stock’s 50 day simple moving average is $77.08 and its 200 day simple moving average is $80.70. The stock has a market cap of $1.81 billion, a PE ratio of 20.48 and a beta of 0.46. ANI Pharmaceuticals, Inc. has a 12 month low of $56.71 and a 12 month high of $99.50. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.77. The firm had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company’s revenue for the quarter was up 20.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.73 EPS for the current year.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently bought and sold shares of ANIP. Arrowstreet Capital Limited Partnership bought a new position in ANI Pharmaceuticals during the third quarter worth $32,992,000. Balyasny Asset Management L.P. raised its stake in ANI Pharmaceuticals by 2,785.7% during the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock worth $26,211,000 after buying an additional 276,233 shares during the last quarter. Divisadero Street Capital Management LP bought a new position in ANI Pharmaceuticals during the third quarter worth $21,454,000. Rubric Capital Management LP raised its stake in ANI Pharmaceuticals by 354.7% during the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock worth $16,813,000 after buying an additional 200,998 shares during the last quarter. Finally, UBS Group AG raised its stake in ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after buying an additional 185,172 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on ANIP. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Guggenheim raised their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Finally, Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, April 15th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $107.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.